665 related articles for article (PubMed ID: 34225440)
1. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
Wang L; Liu XE; Zhuang H
Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
4. [Research advances in diagnosis of non-alcoholic fatty liver disease].
Wang JH; Yu CH
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):115-118. PubMed ID: 28297797
[TBL] [Abstract][Full Text] [Related]
5. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease.
Perakakis N; Stefanakis K; Mantzoros CS
Metabolism; 2020 Oct; 111S():154320. PubMed ID: 32712221
[TBL] [Abstract][Full Text] [Related]
6. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
7. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Alkhouri N; Feldstein AE
Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
11. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Kage M; Aishima S; Kusano H; Yano H
J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
[TBL] [Abstract][Full Text] [Related]
12. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
13. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
14. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
[TBL] [Abstract][Full Text] [Related]
15. [Histopathological diagnosis and differential diagnosis of nonalcoholic fatty liver disease].
Theurer S; Kälsch J; Schwertheim S; Kathemann S; Baba HA
Pathologe; 2020 Sep; 41(5):434-443. PubMed ID: 32533233
[TBL] [Abstract][Full Text] [Related]
16. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.
Zeng Y; He H; An Z
Dis Markers; 2022; 2022():1254014. PubMed ID: 35811662
[TBL] [Abstract][Full Text] [Related]
17. The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD).
Carulli L; Zanca G; Schepis F; Villa E
Metabolites; 2019 Feb; 9(2):. PubMed ID: 30717274
[TBL] [Abstract][Full Text] [Related]
18. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
19. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.
Albhaisi S; Sanyal AJ
Pharmaceut Med; 2019 Dec; 33(6):451-463. PubMed ID: 31933238
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
